Chemokines News and Research

RSS

Research illuminates how primary colorectal tumors contribute to premetastatic 'niche' formation

Primary colorectal tumors secrete VEGF-A, inducing CXCL1 and CXCR2-positive myeloid-derived suppressor cell (MDSC) recruitment at distant sites and establishing niches for future metastases, report Medical University of South Carolina investigators in an article published online ahead of print on April 28, 2017 by Cancer Research.

10 May 2017

‘Geneva signature’ evaluates safety and immunogenicity of promising anti-Ebola virus vaccine

An international team based at Geneva University Hospitals and at the University of Geneva, Switzerland, has succeeded in defining a "signature" composed of a small number of inflammatory markers that can be monitored in order to understand how a promising anti-Ebola virus vaccine stimulates the immune system.

19 Apr 2017

Study of interactions between chemokines pinpoints potential targets for treatment of inflammation

Signal molecules called chemokines often work in tandem to recruit specific sets of immune cells to sites of tissue damage.

7 Apr 2017

New ‘release and kill’ strategy may shorten treatment periods for patients with tuberculosis

Mycobacterium tuberculosis has been called "the perfect pathogen." These bacteria hijack human macrophages, persist inside the cells to evade immune destruction, and then prevent the macrophage from undergoing programmed cell death.

8 Feb 2017

Novel approach for imaging immune cell movements identifies initial steps in inflammatory arthritis

Using a novel approach for imaging the movement of immune cells in living animals, researchers from the Massachusetts General Hospital Center for Immunology and Inflammatory Diseases have identified what appear to be the initial steps leading to joint inflammation in a model of inflammatory arthritis.

20 Jan 2017

Researchers uncover structure of cancer cell receptor protein that paves way for drug development

A team of researchers from Case Western Reserve University School of Medicine has helped uncover the elusive structure of a cancer cell receptor protein that can be leveraged to fight disease progression.

19 Jan 2017

New duo therapy offers hope for 'super blockage' of over-active immune system

A combination of two potential drugs gives hope of a 'super blockage' of an over-active immune system, Leiden researchers report in Nature. The breakthrough came from the crystallisation of a membrane protein.

15 Dec 2016

Oral cavity bacterium linked to development and progression of esophageal cancer

A type of bacterium usually found in the human mouth, Fusobacterium nucleatum, has been found to be related to the prognosis of esophageal cancer in Japanese patients by researchers from Kumamoto University, Japan.

9 Dec 2016

Low-dose chemotherapy regimens may be more effective at treating certain breast and pancreatic cancer types

Conventional, high-dose chemotherapy treatments can cause the fibroblast cells surrounding tumors to secrete proteins that promote the tumors' recurrence in more aggressive forms, researchers at Taipei Medical University and the National Institute of Cancer Research in Taiwan and University of California, San Francisco, have discovered.

24 Nov 2016

New study identifies novel target for treatment of Graves' disease and other scarring eye conditions

A new class of therapies may be on the horizon for thyroid eye disease (TED) and other destructive scarring conditions.

11 Nov 2016

Researchers identify protein linked to negative effects of senescence

Cellular senescence is a state in which normal healthy cells do not have the ability to divide. Senescence can occur when cancer-causing genes are activated in normal cells or when chemotherapy is used on cancer cells.

1 Nov 2016

Novel biomarkers enhance power to predict therapeutic efficacy in LN prognostic models

Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.

12 Oct 2016

Tumor microenvironment acts as source of resistance to cancer therapies

Researchers at Bellvitge Biomedical Research Institute have published a new Oncotarget work which highlights the importance of the tumor environment as a source of resistance to treatment in colorectal cancer, the fourth most common cancer and the leading cause of cancer death worldwide.

7 Sep 2016

Existing anti-inflammatory drugs may be effective in treating epilepsy

In epileptic patients, seizures lead to an increased level of inflammation-related proteins called chemokines in the brain, and systemic inflammation likely helps trigger and promote the recurrence of seizures, making inflammation a promising new target for anticonvulsant therapy.

6 Jul 2016

Maternal immune dysfunction linked to risk of autism with intellectual disability in children

Pregnant women with higher levels of inflammatory cytokines and chemokines, proteins that control communication between cells of the immune system, may be at significantly greater risk of having a child with autism combined with intellectual disability, researchers with the UC Davis MIND Institute have found.

8 Jun 2016

Research shows spleen MZ B cells produce signaling proteins involved in inflammatory responses

The inability to adequately respond to infection can cause a whole-body state of inflammation known as sepsis. This can eventually lead to systemic inflammatory response syndrome (SIRS), and even death.

9 May 2016

Pre-TKI cytokine profiling predicts CP-CML outcome

Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase-chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests.

20 Apr 2016

HDAC inhibitors could improve activity of immunotherapeutic antibodies in lung cancer patients

Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and melanoma; however, only 20 percent of lung cancer patients show a response to these agents.

2 Apr 2016

New thematic issue highlights link between hyperuricemia, gout and kidney disease

The increasing prevalence of both gout and chronic kidney disease has led to a growing interest in the association between hyperuricemia (an abnormally high level of uric acid in the blood) and kidney disease.

29 Mar 2016

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C.

8 Mar 2016